◼ Archived
Business
🔮 Archynetys predicts: fades by tomorrow — graded ✓ correct
Wedbush Initiates SpaceX Coverage With 'Outperform' Rating, $190 Price Target
4sources
6articles
3velocity
+0%since first seen
20d agofirst detected
🌍 Cross-language spread
Archynetys detected this story across 2 language editions of the world's news.
🇬🇧
English
Jul 1, 18:00 UTC
🇫🇷
French
Jul 2, 08:34 UTC · Les Numériques
Detected by matching proper nouns and figures that survive translation. Times reflect when each edition's coverage was first indexed.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Coverage (6)
- SpaceX Stock Falls After Firm Calls Valuation ‘Catastrophic’ Barron's · 20d ago
- SpaceX Investors Are Having Another Brutal Day Futurism · 20d ago
- SpaceX Stock Is Down 22% From Its Peak. History Says This Is How Low It Will Go -- and What Comes Next. Yahoo Finance · 20d ago
- SpaceX Faces Post-IPO Volatility, Yet Wall Street Predicts Significant Stock Price Gains Investopedia · 21d ago
- Tech bull Ives initiates SpaceX with Outperform rating, $190 price target Yahoo Finance · 21d ago
- Dan Ives Just Gave Elon Musk and SpaceX Some Great News Yahoo Finance · 21d ago
Related trends
▲ Peaking
Business
Is the All-New Range Rover GT Stepping on Jaguar’s Tail?
▲ Peaking
Business
ChatGPT Led to a Man’s Near-Fatal Health Crisis, Lawsuit Claims
OpenAI faces lawsuits alleging that ChatGPT encouraged an Alabama woman's suicide and contributed to a man's near-fatal health crisis.
▲ Peaking
Business
Google Expands in Miami After Its Billionaire Founders Buy Homes
Google is significantly expanding its Miami footprint following the relocation of its billionaire co-founders to South Florida.
▲ Peaking
Business
Nike Reboots Its Troubled China Operations
▲ Peaking
Business
US Senate panel approves bill to crack down on Chinese vehicles
▲ Peaking
Business
Why Arrowhead Shot Sky-High, While Ionis Toppled
Arrowhead Pharmaceuticals shares surged following positive Phase 3 trial results for its lipid-lowering drug, impacting competitor Ionis.